FDA approves new drug reflecting cutting-edge, ’tissue-agnostic’ effort to beat cancer

Vitrakvi, a new tissue-agnostic cancer drug — or one that targets tumors caused by TRK fusion — has been approved by the FDA, reports John Bacon for USA Today.

For many patients, this is the only possible treatment for their disease. “There had been no treatment for cancers that frequently express this mutation,” the FDA announced.

Bayer, the company behind the drug has promised to make it affordable to all who need it.

This entry was posted in Health Issues. Bookmark the permalink.
  • One World Observatory

    Learn more about the One World Observatory complimentary ticket program.

  • Categories

  • From the Newsletter

  • Upcoming Events

    1. Remember those who have died of COVID-19

      March 4 @ 8:00 am - May 31 @ 5:00 pm
    2. Sign up to read names at FDNY 343 Memorial Club September 11th Memorial Ceremony, Summerfield, FL

      March 17 @ 8:00 am - July 1 @ 5:00 pm
    3. Arlington Historical Society 9/11 Essay Contest for Grades 8-12

      April 8 @ 8:00 am - May 21 @ 5:00 pm
    4. 9/11 exhibit in Monmouth County, NJ seeks stories of 9/11

      April 29 @ 8:00 am - May 20 @ 5:00 pm
    5. Get Up for Glioblastoma Virtual Half-Marathon

      May 1 @ 8:00 am - May 31 @ 5:00 pm